Related Experiment Videos
[Ulcerating haemorrhagic colitis induced by celecoxib]
P Rey1, D Andriamanantena, C Carrère
1Service des maladies digestives, Fédération de médecine, Hôpital d'Instruction des Armées Legouest, Metz. philippe.rey@santesurf.com
Presse Medicale (Paris, France : 1983)
|May 21, 2005
Summary
Celecoxib, a cyclooxygenase-2 inhibitor, may cause hemorrhagic ulcerated colitis. This case report highlights potential colic toxicity of anti-Cox2 drugs, emphasizing the need for reporting side effects.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Cyclooxygenase-2 (COX-2) inhibitors were developed to reduce the gastrointestinal toxicity associated with nonsteroidal anti-inflammatory drugs (NSAIDs).
- The effects of COX-2 inhibitors on the colonic mucosa remain largely uncharacterized.
Observation:
- A 38-year-old woman with no prior digestive history developed acute colitis with hemorrhage and ulceration.
- Symptoms began two days after initiating celecoxib (200 mg/day) for sciatica.
Findings:
- The intrinsic causality of celecoxib in inducing colitis was deemed highly probable based on chronological and semiological evidence.
- Extrinsic factors were considered, referencing existing literature primarily on rofecoxib.
Implications:
- This case is the first reported instance of hemorrhagic ulcerated colitis linked to celecoxib use.
- It confirms the potential for colonic toxicity with anti-COX-2 agents and identifies a novel cause of acute colitis.
- Increased reporting of colonic side effects associated with COX-2 inhibitors is crucial due to their recent market introduction.